Amazon teams up with Fred Hutchinson to launch cancer vaccine clinical trial
Fred Hutchinson is sponsoring the Phase 1 trial, while Amazon are contributing scientific and machine learning expertise
E-commerce giant Amazon confirmed this week that it is collaborating with the US-based Fred Hutchinson Cancer Research Center to develop cancer vaccines, and recently launched an FDA-approved clinical trial.
Amazon and Fred Hutchinson are currently in the process of recruiting 20 participants over the age of 18 for the Phase 1 trial, which will test the safety and efficacy of vaccines for the treatment of breast cancer and melanoma, according to a recent filing. The vaccine candidate is described as a ‘personalized neo-antigen peptide vaccine’ that combines multiple patient specific neo-antigens.
The study began on June 9, 2022 and is expected to be complete by November 1, 2023. Fred Hutchinson is listed as the study’s sponsor, while Amazon is listed as a collaborator in the filing.
Amazon and Fred Hutchinson have both confirmed the partnership.
Speaking to CPHI, an Amazon spokesperson said the company would be contributing ‘scientific and machine learning expertise’ to the partnership.
They continued: ‘It’s very early, but Fred Hutch recently received permission from the U.S. Food and Drug Administration to proceed with a Phase I clinical trial, and it’s unclear whether it will be successful. This will be a long, multi-year process—should it progress, we would be open to working with other organizations in health care and life sciences that might also be interested in similar efforts.’
Fred Hutchinson added that ‘success is by no means guaranteed’ in a statement to CPHI.
The collaboration is the latest attempt by Amazon to expand its healthcare offering and utilise the work done by its internal R&D teams. In 2020 the company launched an online pharmacy, called Amazon Pharmacy, and in 2021 expanded its telehealth service, Amazon Care. It has also explored the development of at-home medical diagnostics.
Related News
-
News Merck invests US$1 billion in new USA-based vaccine facility
Merck annouces the opening of a new state-of-the-art vaccine production plant in Durham, North Carolina, USA, in efforts to bring pharmaceutical product development onto home soil in face of new import tariffs. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Trump's federal funding shift could stifle biotech innovation
Over a month into the second term of Donald Trump’s presidency and we have already seen some big changes affecting the healthcare industry. -
News Sanofi receives FDA warning over contamination at manufacturing site
The FDA issues a warning letter to Sanofi over contamination violations found at the Framingham biologics facility, in Boston, MA, USA.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance